Related coverage linked through entity extraction aliases.
May 20, 2026
A phase I trial and a preclinical study found viral immunotherapy triggered T cell responses in glioblastoma. The clinical study enrolled 41 patients; the mouse study showed prolonged survival and immunologic memory.
Apr 23, 2026
Nature Communications findings showed NR2F6 deletion revived exhausted CAR-T cells and boosted activity against solid tumors. In murine models, modified cells drove tumor regression, prolonged survival and resistance to rechallenge.
Apr 21, 2026
Wafik S. El-Deiry highlighted p53 research and the August 2025 approval of dordaviprone/modeyso, the first treatment for diffuse gliomas with H3K27M mutations. Separate posts also described glioblastoma precision oncology discussions and a lifetime achievement award in Mumbai.
Apr 19, 2026
Tango Therapeutics said it plans to start a pivotal 300-patient randomized vopimetostat trial in second-line pancreatic cancer this year after FDA interactions. The company also reported early combination enrollment with daraxonrasib and zoldonrasib and said more monotherapy and combination data are expected later this year.
Apr 10, 2026
Champions Oncology said it will present eight poster presentations at AACR 2026 in San Diego on April 17-22. The studies cover KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, ADCs and CAR-T therapies.
Mar 24, 2026
A clinical trial combining laser interstitial thermal therapy with pembrolizumab immunotherapy showed nearly half of recurrent high-grade astrocytoma patients alive at 18 months, far exceeding typical survival. Separate research reveals steroids make glioblastoma cells vulnerable to dietary interventions targeting their altered metabolism.
Mar 22, 2026
Researchers have developed new immunotherapy approaches including internal immune cell reprogramming and CD40-based therapies showing promising results in early trials. Meanwhile, glioblastoma remains resistant to current immunotherapies due to blood-brain barrier constraints, though advances in antibody engineering offer new potential strategies.
Mar 20, 2026
DelveInsight pipeline reports reveal robust clinical development across three cancer indications, with 45+ companies advancing cutaneous squamous cell carcinoma therapies, 70+ companies developing liver cancer treatments, and multiple hepatocellular carcinoma candidates receiving FDA designations in 2025-2026.
Mar 19, 2026
The U.S. FDA has granted Fast Track designation to FluoGuide's FG001 as an intraoperative imaging agent for high-grade glioma surgical resection. The designation follows IND clearance in January and enables accelerated development and regulatory review.
Mar 18, 2026
Diakonos Oncology's Phase 2 glioblastoma trial of DOC1021 continues after independent safety review found no concerns. The company will present clinical data on the dendritic cell therapy at AACR and AAN conferences in April 2026.
Mar 16, 2026
Telix Pharmaceuticals has submitted regulatory applications for TLX101-Px, a brain cancer imaging agent, to both the European Medicines Agency and the U.S. Food and Drug Administration, seeking approval for glioma diagnosis and treatment monitoring.
Mar 13, 2026
The blood-brain barrier continues to block most treatments for glioblastoma and central nervous system diseases, with only 0.01% of biologic drugs reaching the brain. New intellectual property coverage and synthetic methods aim to address delivery challenges.
Mar 10, 2026
Recent publications and collaborations advance glioblastoma research through blood-based microRNA diagnostics, combination immunotherapy trials, and identification of MOV10 as a prognostic biomarker and therapeutic target.
Feb 27, 2026
CAR T-cell therapy market advances with AI-driven manufacturing improvements and over 250 companies developing 500+ drug candidates, including breakthrough solid tumor treatments and GPC3-targeted therapies for hepatocellular carcinoma.
Feb 27, 2026
A clinical trial combining laser interstitial thermal therapy with pembrolizumab shows nearly half of patients with recurrent high-grade astrocytoma alive at 18 months, compared to zero in the control group.
Feb 19, 2026
A comprehensive market report reveals over 180 companies are developing more than 200 PD-1 and PD-L1 inhibitor drugs, with recent fast-track designations and successful Phase III trial results driving expansion in cancer immunotherapy.
Feb 26, 2026
Northwestern Medicine researchers identified a potent immunotherapy approach targeting the STING pathway for meningiomas, the most common primary brain tumor. The experimental drug STING agonist 8803 triggered tumor cell death and immune responses in human samples and mouse models.
Feb 26, 2026
Researchers have developed a remote-controlled CAR T-cell therapy that can be switched off on demand using venetoclax, while new engineering strategies aim to overcome barriers in treating glioblastoma and other solid tumors.
Feb 24, 2026
Southern RNA and Providence Therapeutics will support a clinical trial testing personalized mRNA cancer vaccines for children with treatment-resistant brain tumors, marking the first multi-site pediatric study of its kind.
Feb 21, 2026
The U.S. Food and Drug Administration has cleared FluoGuide's Investigational New Drug application for FG001, enabling the company to proceed with a Phase 2 registration trial in high-grade glioma patients with first enrollment expected in Q2 2026.
